FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q57954344> ?p ?o ?g. }

• Q57954344 description "article scientifique publié en 2018" @default.
• Q57954344 description "artículu científicu espublizáu en setiembre de 2018" @default.
• Q57954344 description "im September 2018 veröffentlichter wissenschaftlicher Artikel" @default.
• Q57954344 description "scientific article published on 27 September 2018" @default.
• Q57954344 description "wetenschappelijk artikel" @default.
• Q57954344 description "наукова стаття, опублікована в листопаді 2018" @default.
• Q57954344 description "գիտական հոդված հրատարակված 2018 թվականի սեպտեմբերի 27-ին" @default.
• Q57954344 name "Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)" @default.
• Q57954344 name "Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)" @default.
• Q57954344 name "Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial" @default.
• Q57954344 type Item @default.
• Q57954344 label "Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)" @default.
• Q57954344 label "Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)" @default.
• Q57954344 label "Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial" @default.
• Q57954344 prefLabel "Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)" @default.
• Q57954344 prefLabel "Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)" @default.
• Q57954344 prefLabel "Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial" @default.
• Q57954344 P1433 Q57954344-EEE2F428-F2CE-423C-A5F2-794ACB6F2B2A @default.
• Q57954344 P1476 Q57954344-FC045DD2-425C-4069-B402-B8291AE4CCAB @default.
• Q57954344 P2093 Q57954344-051FBEA7-D60F-4BEA-B8AE-E9E93E3FEA4B @default.
• Q57954344 P2093 Q57954344-071C8392-A919-442F-85C3-24B8E5457C15 @default.
• Q57954344 P2093 Q57954344-097CD7DA-A7B4-4903-9914-C1F06E08D5F3 @default.
• Q57954344 P2093 Q57954344-0E3F4CC6-B14B-4231-AE3D-1B811BB0F8A4 @default.
• Q57954344 P2093 Q57954344-666ABE54-A4C6-4BD7-9E96-1726C170C407 @default.
• Q57954344 P2093 Q57954344-6E0CD696-17B2-4E3F-AF7E-D49517811CF7 @default.
• Q57954344 P2093 Q57954344-704769F9-0CD0-4A9F-8C4D-94FEDA0A3BED @default.
• Q57954344 P2093 Q57954344-8028A68B-B218-40F8-B2DC-A98CA21438D0 @default.
• Q57954344 P2093 Q57954344-89171E3D-452D-431C-A4EE-EC678D9CD6E9 @default.
• Q57954344 P2093 Q57954344-9F536A8C-201E-4BA6-B180-255784E02C4E @default.
• Q57954344 P2093 Q57954344-A0696E52-71CB-4813-938F-C51CF3F9E7BB @default.
• Q57954344 P2093 Q57954344-A279014E-11D3-40B9-B0C5-816E5B95B165 @default.
• Q57954344 P2093 Q57954344-B046A136-1B31-42F4-8723-2A2E47D88CD0 @default.
• Q57954344 P2093 Q57954344-C295668F-BC35-466C-99CA-8B4BB8A7C49B @default.
• Q57954344 P2093 Q57954344-DB083D5A-AA55-4013-86C9-CC17303D5536 @default.
• Q57954344 P2093 Q57954344-DF95ADE0-5F8A-4DE5-80C1-00DE8059A095 @default.
• Q57954344 P2093 Q57954344-F2CB56D4-1F3D-469C-87DD-BB4CE53285D1 @default.
• Q57954344 P2093 Q57954344-F5633DE8-F210-4BDE-A27A-642364F35798 @default.
• Q57954344 P2093 Q57954344-F8018D50-DD12-497F-A537-33CE6E057E2F @default.
• Q57954344 P2093 Q57954344-FAC255D2-BCF2-46EA-80ED-9E4801CC0286 @default.
• Q57954344 P2860 Q57954344-095550DC-941E-4A29-9A74-537E775B988E @default.
• Q57954344 P2860 Q57954344-0A1876B1-A294-463D-A82A-D82E49CB10D8 @default.
• Q57954344 P2860 Q57954344-0E4A845E-C6DE-44E5-BFF4-7C685C084824 @default.
• Q57954344 P2860 Q57954344-15C083A5-20A5-4761-BD89-A451961DA590 @default.
• Q57954344 P2860 Q57954344-1BA7F405-202C-47DE-BF87-1B6B6067C86F @default.
• Q57954344 P2860 Q57954344-1CB53856-1EAA-44E3-9770-85FDA2C8C2FA @default.
• Q57954344 P2860 Q57954344-2D5E6E71-E894-4770-A591-819B458C2F10 @default.
• Q57954344 P2860 Q57954344-413FAB88-76F0-4648-AB82-95B7B99A9AE1 @default.
• Q57954344 P2860 Q57954344-434D9433-8E63-4EF8-AE5A-440787872046 @default.
• Q57954344 P2860 Q57954344-460FC401-0EDB-4A8B-983E-BE361C211C1E @default.
• Q57954344 P2860 Q57954344-5474BE16-72D2-458A-A2D0-84247D14C6C4 @default.
• Q57954344 P2860 Q57954344-5D732AEF-19E0-437C-B3E3-D9A8E415B575 @default.
• Q57954344 P2860 Q57954344-6ABF2EF0-68B6-4C2B-A3BE-1EB4EE9BB7F7 @default.
• Q57954344 P2860 Q57954344-72240A1C-692C-4A60-8D54-C61EE5B2D7BA @default.
• Q57954344 P2860 Q57954344-7DB01065-D166-4C50-A164-D5B9F75455BE @default.
• Q57954344 P2860 Q57954344-88DB62B8-03B2-4973-A5AB-33655FCB4010 @default.
• Q57954344 P2860 Q57954344-9E64CEE2-954B-49FC-A457-7B8E820A2CEE @default.
• Q57954344 P2860 Q57954344-9F00169E-E3A9-456F-AE1A-AFC9B3DC6AD9 @default.
• Q57954344 P2860 Q57954344-ADA8F7A5-C275-4B98-86E0-5097E74DA1C6 @default.
• Q57954344 P2860 Q57954344-ADBF3A9D-7811-48E8-8E72-992E092DCCC2 @default.
• Q57954344 P2860 Q57954344-C143AE4D-3A6B-4822-B6E1-5B426FBBC4C7 @default.
• Q57954344 P2860 Q57954344-DD28136D-FA29-430C-BF8C-D698D8DF5244 @default.
• Q57954344 P2860 Q57954344-E39B3615-71C4-4B43-A4AD-41C20EEA3B18 @default.
• Q57954344 P2860 Q57954344-F3D3D940-A5A8-48A3-B458-9A3E6E4DA39B @default.
• Q57954344 P2860 Q57954344-F63279EB-999A-40D9-8620-DF012DB8C9AB @default.
• Q57954344 P304 Q57954344-9D84BD6A-0839-40DF-8319-D15EAA3C1711 @default.
• Q57954344 P31 Q57954344-42A2DF12-CC87-45CA-86B8-00141F0405C2 @default.
• Q57954344 P356 Q57954344-B9C0711E-AE1E-4011-A78F-3CA63507791A @default.
• Q57954344 P478 Q57954344-90E25D38-2C0D-4AE4-995E-DF619F1FA4D3 @default.
• Q57954344 P50 Q57954344-50A7C426-50F9-4862-A6A3-3A097FF948C8 @default.
• Q57954344 P50 Q57954344-86296B9C-B516-426A-984A-799197544E06 @default.
• Q57954344 P50 Q57954344-8A78175E-5626-46AF-92BD-1B18C73477CD @default.
• Q57954344 P577 Q57954344-6D88119A-F191-4AB4-B5E4-022FD6FA168C @default.
• Q57954344 P698 Q57954344-DAC0AF2E-0C03-43CE-BCDD-C54E3BBD3865 @default.
• Q57954344 P921 Q57954344-E530A5D0-0AE7-4155-A3AA-E1E7CFBF6681 @default.
• Q57954344 P932 Q57954344-12DADAC9-02D3-4BB0-A41A-6C7ECA10E171 @default.
• Q57954344 P356 J.JBO.2018.09.008 @default.
• Q57954344 P698 30591866 @default.
• Q57954344 P1433 Q26842683 @default.
• Q57954344 P1476 "Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)" @default.
• Q57954344 P2093 "A Bowman" @default.
• Q57954344 P2093 "C Wilson" @default.
• Q57954344 P2093 "D Cameron" @default.
• Q57954344 P2093 "D Dodwell" @default.
• Q57954344 P2093 "D Ritchie" @default.
• Q57954344 P2093 "G Bertelli" @default.
• Q57954344 P2093 "J C Tercero" @default.
• Q57954344 P2093 "J E Brown" @default.
• Q57954344 P2093 "J Jean-Mairet" @default.
• Q57954344 P2093 "J Joffe" @default.
• Q57954344 P2093 "J L Passos-Coelho" @default.
• Q57954344 P2093 "M Gil" @default.
• Q57954344 P2093 "M Keane" @default.
• Q57954344 P2093 "P Barrett-Lee" @default.
• Q57954344 P2093 "R Bell" @default.
• Q57954344 P2093 "R E Coleman" @default.
• Q57954344 P2093 "R H De Boer" @default.
• Q57954344 P2093 "S O'Reilly" @default.
• Q57954344 P2093 "V Liversedge" @default.
• Q57954344 P2093 "W Gregory" @default.
• Q57954344 P2860 Q24630719 @default.

• next